Health Care·Biotechnology·$5.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.05 | N/A | -7.47% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.05 | N/A | -7.47% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current financial performance and the road ahead. They did not provide any updates on guidance, indicating uncertainty.
Management highlighted ongoing challenges in achieving profitability.
They emphasized the need for continued investment in product development.
No specific updates were provided regarding future revenue expectations.
The earnings report indicates that Rhythm Pharmaceuticals is still facing challenges, particularly in controlling losses. The stock's 2.7% decline reflects investor concerns about the company's path to profitability and lack of guidance. Without clear expectations for future performance, investors may remain cautious.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ENTERPRISE PRODS PAR
May 2, 2022